 Connection
Martin Krsak to Anti-Bacterial Agents
This is a "connection" page, showing publications Martin Krsak has written about Anti-Bacterial Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.928 |
|
|
|
-
Krsak M, Morrisette T, Miller M, Molina K, Huang M, Damioli L, Pisney L, Wong M, Poeschla E. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. Pharmacotherapy. 2020 05; 40(5):469-478.
Score: 0.363
-
Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019 08 01; 74(8):2405-2416.
Score: 0.345
-
Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clin Pharmacokinet. 2022 03; 61(3):363-374.
Score: 0.102
-
Krsak M, Damioli L. Is 2 Weeks of Treatment Enough for Cortical Bone Osteomyelitis? Clin Infect Dis. 2020 01 01; 70(1):179.
Score: 0.089
-
Cortes-Penfield N, Krsak M, Damioli L, Henry M, Seidelman J, Hewlett A, Certain L. How We Approach Suppressive Antibiotic Therapy Following Debridement, Antibiotics, and Implant Retention for Prosthetic Joint Infection. Clin Infect Dis. 2024 01 25; 78(1):188-198.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|